US7252829B1
(en)
|
1998-06-17 |
2007-08-07 |
Idm Pharma, Inc. |
HLA binding peptides and their uses
|
JPH10510988A
(ja)
*
|
1994-12-14 |
1998-10-27 |
ザ スクリップス リサーチ インスティテュート |
腫瘍−特異的細胞毒性t細胞のインビボ活性化
|
US6514942B1
(en)
*
|
1995-03-14 |
2003-02-04 |
The Board Of Regents, The University Of Texas System |
Methods and compositions for stimulating T-lymphocytes
|
US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
*
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US8038994B2
(en)
|
1996-05-15 |
2011-10-18 |
Quest Pharmatech Inc. |
Combination therapy for treating disease
|
US20080220012A1
(en)
*
|
1996-05-15 |
2008-09-11 |
Ragupathy Madiyalakan |
Therapeutic Compositions that alter the immune response
|
EP0910407B1
(de)
*
|
1996-05-15 |
2003-02-26 |
Altarex Corp. |
Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
JP2001512306A
(ja)
|
1997-01-08 |
2001-08-21 |
ライフ テクノロジーズ,インコーポレイテッド |
タンパク質の産生方法
|
AU747577B2
(en)
*
|
1997-01-30 |
2002-05-16 |
Novartis Vaccines And Diagnostics, Inc. |
Use of microparticles with adsorbed antigen to stimulate immune responses
|
US6884435B1
(en)
*
|
1997-01-30 |
2005-04-26 |
Chiron Corporation |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
US20040202680A1
(en)
*
|
1997-01-30 |
2004-10-14 |
O'hagan Derek |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
JP2002514573A
(ja)
*
|
1998-05-08 |
2002-05-21 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
能動的なワクチン接種のための組成物および方法
|
GB9810040D0
(en)
|
1998-05-11 |
1998-07-08 |
Univ Nottingham |
Blood borne tumour markers
|
CN100531798C
(zh)
|
1998-08-11 |
2009-08-26 |
拜奥根Idec公司 |
包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
|
US6573043B1
(en)
*
|
1998-10-07 |
2003-06-03 |
Genentech, Inc. |
Tissue analysis and kits therefor
|
KR20010099788A
(ko)
*
|
1998-11-09 |
2001-11-09 |
케네쓰 제이. 울코트 |
Bmt 또는 pbsc 이식을 받은 환자의 키메라항-cd20 항체 치료법
|
DK1616572T3
(da)
|
1998-11-09 |
2010-12-06 |
Biogen Idec Inc |
Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
|
US6541214B1
(en)
*
|
1998-11-13 |
2003-04-01 |
Oregon Heath Science University |
N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
|
GB9827228D0
(en)
|
1998-12-10 |
1999-02-03 |
Univ Nottingham |
Cancer detection method and reagents
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
US7396810B1
(en)
*
|
2000-08-14 |
2008-07-08 |
Oregon Health Sciences University |
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
DE60041808D1
(de)
|
1999-01-27 |
2009-04-30 |
Cornell Res Foundation Inc |
Behandlung von mit her-2/neu-überexprimierung einhergehendem krebs
|
US7198920B1
(en)
|
1999-01-29 |
2007-04-03 |
Corika Corporation |
HER-2/neu fusion proteins
|
NZ513062A
(en)
*
|
1999-01-29 |
2003-10-31 |
Smithkline Beecham |
HER-2/neu fusion proteins
|
WO2000054839A2
(en)
*
|
1999-03-15 |
2000-09-21 |
Introgen Therapeutics, Inc. |
Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
|
EP1754488A1
(de)
|
1999-05-24 |
2007-02-21 |
Introgen Therapeutics, Inc. |
Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
|
KR20030000011A
(ko)
*
|
1999-05-25 |
2003-01-03 |
휴먼 게놈 사이언시즈, 인크. |
Meth-1 및 meth-2 폴리뉴클레오티드 및폴리펩티드
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
DK1189634T3
(da)
*
|
1999-06-25 |
2007-06-25 |
Genentech Inc |
Behandling af prostatacancer med anti-ErbB2-antistoffer
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
AU6620300A
(en)
*
|
1999-08-03 |
2001-02-19 |
Ohio State University, The |
Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
ES2330301T3
(es)
*
|
1999-08-27 |
2009-12-09 |
Genentech, Inc. |
Dosificaciones para tratamiento con anticuerpos anti-erbb2.
|
US20030157119A1
(en)
*
|
1999-09-22 |
2003-08-21 |
Corixa Corporation |
Methods for diagnosis and therapy of hematological and virus-associated malignancies
|
AU7710300A
(en)
*
|
1999-09-22 |
2001-04-24 |
Corixa Corporation |
Methods for diagnosis and therapy of hematological and virus-associated malignancies
|
US7378096B2
(en)
|
1999-09-30 |
2008-05-27 |
Health Research, Inc. |
Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
|
WO2001023421A2
(en)
*
|
1999-09-30 |
2001-04-05 |
Corixa Corporation |
Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
|
FR2801106B1
(fr)
*
|
1999-11-12 |
2007-10-05 |
Commissariat Energie Atomique |
Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc
|
WO2001041787A1
(en)
*
|
1999-12-10 |
2001-06-14 |
Epimmune Inc. |
INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
|
WO2001048205A2
(en)
*
|
1999-12-29 |
2001-07-05 |
Corixa Corporation |
Murine neu sequences and methods of use therefor
|
US20020039573A1
(en)
*
|
2000-01-21 |
2002-04-04 |
Cheever Martin A. |
Compounds and methods for prevention and treatment of HER-2/neu associated malignancies
|
US6528060B1
(en)
*
|
2000-03-16 |
2003-03-04 |
Genzyme Corporation |
Therapeutic compounds
|
AU4791901A
(en)
*
|
2000-03-30 |
2001-10-15 |
Dendreon Corp |
Compositions and methods for dendritic cell-based immunotherapy
|
CA2405290C
(en)
*
|
2000-04-13 |
2011-06-21 |
Bio Life Science Forschungs Und Entwicklungsgesellschaft Mbh |
Vaccine against cancerous diseases
|
WO2001083781A2
(en)
*
|
2000-04-28 |
2001-11-08 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
NZ522444A
(en)
|
2000-05-19 |
2004-09-24 |
Genentech Inc |
Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
|
US10293056B1
(en)
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
US20030232399A1
(en)
*
|
2000-06-14 |
2003-12-18 |
Robertson John Forsyth Russell |
Cancer detection methods and reagents
|
FR2812087B1
(fr)
*
|
2000-07-21 |
2007-05-11 |
Inst Nat Sante Rech Med |
Procede de criblage de peptides utilisables en immunotherapie
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
KR20030048009A
(ko)
*
|
2000-08-14 |
2003-06-18 |
코릭사 코포레이션 |
Her-2/neu 관련 악성 종양의 치료 및 진단용 조성물및 방법
|
AU2001283360A1
(en)
*
|
2000-08-14 |
2002-02-25 |
Corixa Corporation |
Methods for diagnosis and therapy of hematological and virus-associated malignancies
|
PL211151B1
(pl)
|
2000-10-18 |
2012-04-30 |
Glaxosmithkline Biolog Sa |
Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
|
EP1404359A2
(de)
*
|
2000-12-07 |
2004-04-07 |
Board Of Regents, The University Of Texas System |
Behandlungsverfahren mit menschlichem mda-7
|
US20040121946A9
(en)
*
|
2000-12-11 |
2004-06-24 |
John Fikes |
Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
|
US7906492B2
(en)
*
|
2001-01-16 |
2011-03-15 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US7507724B2
(en)
*
|
2001-01-16 |
2009-03-24 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US20040071671A1
(en)
*
|
2001-02-20 |
2004-04-15 |
Leturcq Didier J. |
Cell therapy method for the treatment of tumors
|
ES2306771T3
(es)
*
|
2001-02-20 |
2008-11-16 |
Ortho Mcneil Pharm Inc |
Un metodo de terapia celular para tratamiento de tumores.
|
ES2394293T3
(es)
*
|
2001-02-28 |
2013-01-30 |
Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. |
Vacuna contra cánceres que están asociados con el oncogén HER-2/neu
|
EP2371854B1
(de)
|
2001-03-09 |
2014-05-07 |
Board Of Regents, The University Of Texas System |
Einleitung von Tumorimmunität durch Varianten eines folatbindenden Protein
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AU2002303330B2
(en)
|
2001-05-31 |
2008-07-24 |
Novartis Vaccines And Diagnostics, Inc. |
Chimeric alphavirus replicon particles
|
EP1287831B1
(de)
*
|
2001-09-03 |
2006-11-22 |
Bio Life Science Forschungs- und Entwicklungsges.m.b.H. |
Antigen-Mimotope und Vakzine gegen Krebserkrankungen
|
EP1438583B1
(de)
|
2001-09-20 |
2009-09-16 |
Board of Regents, The University of Texas System |
Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests
|
EP1490101A4
(de)
*
|
2002-03-05 |
2006-09-20 |
Univ Texas |
Verfahren zur verbesserung der immuninduktion mit mda-7
|
WO2003076585A2
(en)
|
2002-03-08 |
2003-09-18 |
Board Of Regents, The University Of Texas System |
Controlled modulation of amino acid side chain length of peptide antigens
|
CA2481796A1
(en)
*
|
2002-04-11 |
2003-10-23 |
Altarex Medical Corporation |
Binding agents and their use in targeting tumor cells
|
AU2003251597A1
(en)
*
|
2002-06-19 |
2004-01-06 |
Abgenix, Inc. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
EP1575500A4
(de)
|
2002-07-12 |
2007-01-03 |
Univ Johns Hopkins |
Mesothelin-vakzine und model systems
|
US20090110702A1
(en)
|
2002-07-12 |
2009-04-30 |
The Johns Hopkins University |
Mesothelin Vaccines and Model Systems and Control of Tumors
|
US9200036B2
(en)
|
2002-07-12 |
2015-12-01 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
US20060099224A1
(en)
|
2002-08-12 |
2006-05-11 |
David Kirn |
Methods and compositions concerning poxviruses and cancer
|
US20080019992A1
(en)
*
|
2002-09-02 |
2008-01-24 |
Christoph Zielinski |
Antigen mimotopes and vaccine against cancerous diseases
|
CN1497255A
(zh)
*
|
2002-10-02 |
2004-05-19 |
���µ�����ҵ��ʽ���� |
被检测体用取样元件、被检测体处理装置及其处理方法
|
AU2003267077A1
(en)
*
|
2002-11-12 |
2004-06-03 |
Millipore Corporation |
Evaporation control device for multiwell plates
|
GB2395270B
(en)
*
|
2002-11-14 |
2006-08-16 |
Univ Nottingham |
Tumour marker proteins and uses thereof
|
JP2006516117A
(ja)
*
|
2002-11-21 |
2006-06-22 |
ジェネンテック・インコーポレーテッド |
抗ErbB2抗体を用いた非悪性疾病または疾患の治療
|
JP2006525787A
(ja)
|
2003-01-03 |
2006-11-16 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
アカゲザルHER2/neu、これをコードするヌクレオチド及びその使用
|
WO2004067716A2
(en)
*
|
2003-01-24 |
2004-08-12 |
Agensys, Inc. |
Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
|
US20060134801A1
(en)
*
|
2003-03-03 |
2006-06-22 |
Board Of Regents, The University Of Texas System |
Methods and compositions involving MDA-7
|
US20080274129A1
(en)
|
2003-04-18 |
2008-11-06 |
Fikes John D |
Hla-A2 Tumor Associated Antigen Peptides and Compositions
|
US20050239088A1
(en)
*
|
2003-05-16 |
2005-10-27 |
Shepard H M |
Intron fusion proteins, and methods of identifying and using same
|
US7178491B2
(en)
*
|
2003-06-05 |
2007-02-20 |
Caterpillar Inc |
Control system and method for engine valve actuator
|
WO2004112825A2
(en)
*
|
2003-06-17 |
2004-12-29 |
Mannkind Corporation |
Combinations of tumor-associated antigens for the treatment of various types of cancers
|
JP4772674B2
(ja)
*
|
2003-07-21 |
2011-09-14 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ヒト上皮成長因子2/neu抗原をコードする合成遺伝子およびその用途
|
GB0321615D0
(en)
|
2003-09-15 |
2003-10-15 |
Glaxo Group Ltd |
Improvements in vaccination
|
AU2004285468B2
(en)
|
2003-10-22 |
2011-02-24 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
|
SG195524A1
(en)
|
2003-11-06 |
2013-12-30 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
WO2005082396A2
(en)
*
|
2003-12-01 |
2005-09-09 |
Introgen Therapeutics, Inc. |
Use of mda-7 to inhibit infection by pathogenic organisms
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
EP1745073A2
(de)
*
|
2004-05-14 |
2007-01-24 |
Receptor Biologix, Inc. |
Isoformen eines zelloberflächenrezeptors und verfahren zu deren identifizierung und anwendung
|
WO2005118806A2
(en)
|
2004-05-28 |
2005-12-15 |
Ambion, Inc. |
METHODS AND COMPOSITIONS INVOLVING MicroRNA
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
EP1765313A2
(de)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Verbindungen als immunstimulatoren
|
SI1791565T1
(sl)
|
2004-09-23 |
2016-08-31 |
Genentech, Inc. |
Cisteinsko konstruirana protitelesa in konjugati
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
CA2583230A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
JP4798801B2
(ja)
*
|
2004-10-06 |
2011-10-19 |
ウェルスタット バイオロジクス コーポレイション |
循環する癌細胞におけるHer−2/neuタンパク質のレベルの上昇の検出および処置
|
CA2850323A1
(en)
|
2004-11-12 |
2006-12-28 |
Asuragen, Inc. |
Methods and compositions involving mirna and mirna inhibitor molecules
|
US20060115862A1
(en)
*
|
2004-11-17 |
2006-06-01 |
Duke University |
Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
|
CN100381460C
(zh)
*
|
2004-11-30 |
2008-04-16 |
北京市肿瘤防治研究所 |
Her-2模拟抗原表位及含有该表位的肽
|
CN101146550B
(zh)
*
|
2004-12-29 |
2013-04-17 |
曼康公司 |
免疫原性组合物用于制备引发和增强免疫应答的试剂盒的用途
|
US20070009484A1
(en)
*
|
2005-02-08 |
2007-01-11 |
Board Of Regents, The University Of Texas System |
Compositions and methods involving MDA-7 for the treatment of cancer
|
ES2443653T3
(es)
*
|
2005-04-20 |
2014-02-20 |
Fred Hutchinson Cancer Research Center |
Procedimientos, composiciones y artículos de fabricación para mejorar la supervivencia de células, tejidos, órganos y organismos
|
CN100398558C
(zh)
*
|
2005-05-10 |
2008-07-02 |
中国人民解放军军事医学科学院基础医学研究所 |
HER2/neu与Herstatin相互作用的活性片段及其编码基因与应用
|
CA2608236A1
(en)
*
|
2005-05-12 |
2006-11-23 |
Introgen Therapeutics, Inc. |
P53 vaccines for the treatment of cancers
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
SI1889059T1
(sl)
|
2005-05-27 |
2009-12-31 |
Oncimmune Ltd |
Izboljšani imunotestni postopek
|
GB2426581A
(en)
*
|
2005-05-27 |
2006-11-29 |
Univ Nottingham |
Immunoassay methods
|
US7691396B2
(en)
|
2005-06-15 |
2010-04-06 |
The Ohio State University Research Foundation |
Chimeric peptides comprising HER-2 B-cell epitopes and measles virus fusion protein T-cell epitopes
|
ES2413079T3
(es)
|
2005-06-17 |
2013-07-15 |
Mannkind Corporation |
Métodos y composiciones para desencadenar respuestas inmunitarias multivalentes contra epítopos dominantes y subdominantes expresados en células cancerosas y estroma tumoral
|
GB0512751D0
(en)
*
|
2005-06-22 |
2005-07-27 |
Glaxo Group Ltd |
New adjuvant
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
US9180149B2
(en)
*
|
2005-09-07 |
2015-11-10 |
Sillajen Biotherapeutics, Inc. |
Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
|
AU2006289683A1
(en)
*
|
2005-09-07 |
2007-03-15 |
Receptor Logic, Ltd. |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
US8945573B2
(en)
|
2005-09-08 |
2015-02-03 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Targeted identification of immunogenic peptides
|
ES2628308T3
(es)
*
|
2005-09-08 |
2017-08-02 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Identificación selectiva de péptidos inmunogénicos
|
CN101355960A
(zh)
|
2005-10-18 |
2009-01-28 |
诺华疫苗和诊断公司 |
使用α病毒复制子颗粒进行粘膜和全身免疫
|
TWI457133B
(zh)
*
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
US8323644B2
(en)
*
|
2006-01-17 |
2012-12-04 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
WO2007084661A2
(en)
*
|
2006-01-17 |
2007-07-26 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US20090053221A1
(en)
*
|
2006-01-17 |
2009-02-26 |
Cheung Nai-Kong V |
Immune response enhancing glucan
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
WO2007109812A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
CA2646539A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
US20100010217A1
(en)
*
|
2006-03-23 |
2010-01-14 |
Valiante Nicholas M |
Methods for the preparation of imidazole-containing compounds
|
US7517270B2
(en)
*
|
2006-05-30 |
2009-04-14 |
Minds-I, Inc. |
Construction system
|
US20090087873A1
(en)
|
2006-07-21 |
2009-04-02 |
Invitrogen Corporation |
Sharply resolving labeled protein molecular weight standards
|
US7972602B2
(en)
*
|
2006-08-11 |
2011-07-05 |
Dendreon Corporation |
Promiscuous HER-2/Neu CD4 T cell epitopes
|
US8574848B2
(en)
*
|
2006-09-13 |
2013-11-05 |
Oncimmune Ltd. |
Immunoassay methods
|
CA2921048C
(en)
|
2006-09-15 |
2018-06-05 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
EP2145001A2
(de)
|
2006-09-19 |
2010-01-20 |
Asuragen, Inc. |
Von mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulierte gene und stoffwechselwege als ziele für einen therapeutischen eingriff
|
US20080075528A1
(en)
*
|
2006-09-22 |
2008-03-27 |
Michael Marzetta |
Construction system
|
EP2084267B1
(de)
*
|
2006-09-26 |
2018-04-11 |
Cedars-Sinai Medical Center |
Krebsstammzellen-antigen-impfstoffe und entsprechende verfahren
|
WO2008039974A2
(en)
|
2006-09-28 |
2008-04-03 |
Cedars-Sinai Medical Center |
Cancer vaccines and vaccination methods
|
US20080131878A1
(en)
*
|
2006-12-05 |
2008-06-05 |
Asuragen, Inc. |
Compositions and Methods for the Detection of Small RNA
|
EP2104734A2
(de)
*
|
2006-12-08 |
2009-09-30 |
Asuragen, INC. |
Mir-20-regulierte gene und pfade als ziele für therapeutische interventionen
|
US8889143B2
(en)
|
2006-12-14 |
2014-11-18 |
Antigen Express, Inc. |
Ii-key/HER-2/neu hybrid cancer vaccine
|
US7935350B2
(en)
*
|
2006-12-14 |
2011-05-03 |
Antigen Express, Inc. |
Ii-key/Her-2/neu hybrid cancer vaccine
|
US7410225B1
(en)
*
|
2007-03-14 |
2008-08-12 |
Minds-I, Inc. |
Multi-part links for endless track
|
KR20080084528A
(ko)
*
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
JP2010525326A
(ja)
*
|
2007-04-19 |
2010-07-22 |
ウェルスタット バイオロジックス コーポレイション |
分離されていない循環癌細胞由来のHer−2/neuタンパク質の上昇したレベルの検出および治療
|
PL2162149T3
(pl)
*
|
2007-06-01 |
2014-04-30 |
Henry M Jackson Found Advancement Military Medicine Inc |
Szczepionka do zapobiegania nawrotowi raka sutka
|
US20090017716A1
(en)
*
|
2007-07-11 |
2009-01-15 |
Michael Marzetta |
Construction system
|
US20090061456A1
(en)
*
|
2007-08-30 |
2009-03-05 |
Allard William J |
Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
|
US8361714B2
(en)
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
US20090117532A1
(en)
*
|
2007-11-01 |
2009-05-07 |
Doyle Gerald V |
Pre-clinical method for monitoring serial changes in circulating breast cancer cells in mice
|
WO2009059450A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Shanghai Jiaotong University |
Peptide ligand directed drug delivery
|
US7841923B2
(en)
*
|
2007-11-13 |
2010-11-30 |
Minds-I, Inc. |
Vehicle axle joint for a toy vehicle
|
WO2009070392A1
(en)
|
2007-11-27 |
2009-06-04 |
Veridex, Llc |
Automated enumeration and characterization of circulating melanoma cells in blood
|
US8071562B2
(en)
|
2007-12-01 |
2011-12-06 |
Mirna Therapeutics, Inc. |
MiR-124 regulated genes and pathways as targets for therapeutic intervention
|
US20090191535A1
(en)
*
|
2007-12-22 |
2009-07-30 |
Mark Carle Connelly |
Method of assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
|
GB0725239D0
(en)
*
|
2007-12-24 |
2008-02-06 |
Oncimmune Ltd |
Calibrator for autoantibody assay
|
EP2990487A1
(de)
|
2008-05-08 |
2016-03-02 |
Asuragen, INC. |
Zusammensetzungen und verfahren in zusammenhang mit der mirna-modulation von neovaskularisation oder angiogenese
|
JP2010006705A
(ja)
*
|
2008-06-13 |
2010-01-14 |
Atlas Antibodies Ab |
Her2サブセット
|
WO2010028066A2
(en)
*
|
2008-09-02 |
2010-03-11 |
Cedars-Sinai Medical Center |
Cd133 epitopes
|
ES2639577T3
(es)
|
2008-12-10 |
2017-10-27 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Vacuna para la prevención de la recurrencia del cáncer de mama
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
JP5718319B2
(ja)
*
|
2009-05-14 |
2015-05-13 |
ネステク ソシエテ アノニム |
Her2標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー
|
WO2010144874A2
(en)
|
2009-06-12 |
2010-12-16 |
University Of Southern California |
Clusterin pharmaceuticals and treatment methods using the same
|
AU2010292172A1
(en)
|
2009-09-09 |
2012-05-03 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
KR101838472B1
(ko)
|
2009-09-14 |
2018-03-15 |
신라젠(주) |
종양 용해 백시니아 바이러스 병용 암 치료요법
|
MX337062B
(es)
|
2009-12-10 |
2016-02-11 |
Ottawa Hospital Res Inst |
Rabdovirus oncolítico.
|
WO2011107100A1
(en)
|
2010-03-03 |
2011-09-09 |
Aarhus Universitet |
Methods and compositions for regulation of herv4
|
JP5972864B2
(ja)
|
2010-04-15 |
2016-08-17 |
メディミューン リミテッド |
ピロロベンゾジアゼピン及びそれらのコンジュゲート
|
KR20130121699A
(ko)
|
2010-05-28 |
2013-11-06 |
테트리스 온라인, 인코포레이티드 |
상호작용 혼성 비동기 컴퓨터 게임 기반구조
|
EP2576613A1
(de)
|
2010-06-07 |
2013-04-10 |
Pfizer Inc. |
Her-2-peptide und impfstoffe
|
AU2011265054B2
(en)
|
2010-06-08 |
2016-09-15 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
CA2816426A1
(en)
|
2010-11-17 |
2012-06-07 |
Genentech, Inc. |
Alaninyl maytansinol antibody conjugates
|
CN103429258B
(zh)
|
2011-01-04 |
2016-03-09 |
新罗杰公司 |
通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性
|
AU2012212105A1
(en)
|
2011-02-03 |
2013-09-12 |
Mirna Therapeutics, Inc. |
Synthetic mimics of miR-124
|
SG10201600836PA
(en)
|
2011-02-03 |
2016-03-30 |
Mirna Therapeutics Inc |
Synthetic mimics of mir-34
|
KR101992502B1
(ko)
|
2011-05-12 |
2019-06-24 |
제넨테크, 인크. |
프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
|
WO2012167382A1
(en)
|
2011-06-08 |
2012-12-13 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions and methods for glioblastoma treatment
|
DK2739310T3
(en)
|
2011-08-05 |
2018-07-16 |
Res Found Dev |
Improved methods and compositions for modulating OLFML3-mediated angiogenesis
|
US10258676B2
(en)
|
2011-09-06 |
2019-04-16 |
Agency For Science, Technology And Research |
Polypeptide vaccine
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
EP2750713B1
(de)
|
2011-10-14 |
2015-09-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine und konjugate daraus
|
JP6170076B2
(ja)
*
|
2012-02-17 |
2017-07-26 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
HER2/neuポリペプチドを発現する癌細胞を認識する能力を有するCD8+T細胞を作製するための方法および材料
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
US20150283233A1
(en)
|
2012-06-15 |
2015-10-08 |
Gencia Corporation |
Compositions and Methods for Enhancing Immune Responses
|
UA114108C2
(uk)
|
2012-07-10 |
2017-04-25 |
Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем |
Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
|
EP2906297B1
(de)
|
2012-10-12 |
2017-12-06 |
ADC Therapeutics SA |
Pyrrolobenzodiazepin-antikörper-konjugate
|
SI2839860T1
(sl)
|
2012-10-12 |
2019-07-31 |
MedImmune Limited, |
Pirolobenzodiazepini in njihovi konjugati
|
EP2906250B1
(de)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepin-anti-psma-antikörperkonjugate
|
JP6392763B2
(ja)
|
2012-10-12 |
2018-09-19 |
エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa |
ピロロベンゾジアゼピン−抗体結合体
|
SI2906296T1
(en)
|
2012-10-12 |
2018-06-29 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
BR112015008173A2
(pt)
|
2012-10-12 |
2017-11-28 |
Adc Therapeutics Sarl |
conjugados de pirrolobenzodiazepina-anticorpo anti-psma
|
US9919056B2
(en)
|
2012-10-12 |
2018-03-20 |
Adc Therapeutics S.A. |
Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
|
WO2014066590A1
(en)
|
2012-10-24 |
2014-05-01 |
Research Development Foundation |
Jam-c antibodies and methods for treatment of cancer
|
EP2935268B2
(de)
|
2012-12-21 |
2021-02-17 |
MedImmune Limited |
Pyrrolobenzodiazepine und konjugate davon
|
AU2013366490B9
(en)
|
2012-12-21 |
2018-02-01 |
Medimmune Limited |
Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
|
WO2014127296A1
(en)
|
2013-02-14 |
2014-08-21 |
Immunocellular Therapeutics, Ltd |
Cancer vaccines and vaccination methods
|
EP2958994B1
(de)
|
2013-02-21 |
2019-05-29 |
Turnstone Limited Partnership |
Impfstoffzusammensetzung
|
SG11201507214SA
(en)
|
2013-03-13 |
2015-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
AU2014230735B2
(en)
|
2013-03-13 |
2018-03-15 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
MX364330B
(es)
|
2013-03-13 |
2019-04-23 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas.
|
AU2014307080B2
(en)
|
2013-08-12 |
2018-06-07 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
CA2921401A1
(en)
|
2013-08-14 |
2015-02-19 |
William Marsh Rice University |
Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
|
CN106659909B
(zh)
|
2013-08-21 |
2022-01-11 |
德克萨斯州大学系统董事会 |
用于靶向连接蛋白半通道的组合物和方法
|
WO2015031735A1
(en)
|
2013-08-29 |
2015-03-05 |
Board Of Regents, The University Of Texas System |
Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
|
AU2014312119B2
(en)
|
2013-08-30 |
2019-09-19 |
Board Of Regents, The University Of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
WO2015052532A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
US9950078B2
(en)
|
2013-10-11 |
2018-04-24 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
LT3076949T
(lt)
|
2013-12-04 |
2019-12-10 |
Univ Texas |
Iš vėžinių ląstelių kilusių egzosomų išskyrimo būdas
|
CN107106700B
(zh)
|
2013-12-16 |
2020-10-30 |
基因泰克公司 |
肽模拟化合物及其抗体-药物缀合物
|
JP6980384B2
(ja)
|
2013-12-16 |
2021-12-15 |
ジェネンテック, インコーポレイテッド |
1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
|
MX371092B
(es)
|
2013-12-16 |
2020-01-16 |
Genentech Inc |
Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
|
WO2016153761A1
(en)
*
|
2015-03-13 |
2016-09-29 |
Czerniecki Brian J |
Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
|
WO2016033105A1
(en)
|
2014-08-29 |
2016-03-03 |
The Board Of Regents Of The University Of Texas System |
Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
|
JP7080053B2
(ja)
|
2014-08-29 |
2022-06-03 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
|
EP3193940A1
(de)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepine und konjugate daraus
|
CA2957354A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3191134B1
(de)
|
2014-09-12 |
2019-11-20 |
Genentech, Inc. |
Anthracyclindisulfidzwischenprodukte, antikörper-wirkstoff-konjugate und verfahren
|
CA2959689A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
|
CN107148285B
(zh)
|
2014-11-25 |
2022-01-04 |
Adc治疗股份有限公司 |
吡咯并苯并二氮杂䓬-抗体缀合物
|
AU2015358532C1
(en)
|
2014-12-03 |
2020-10-29 |
Genentech, Inc. |
Quaternary amine compounds and antibody-drug conjugates thereof
|
US10457737B2
(en)
|
2015-02-09 |
2019-10-29 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
DK3265565T3
(da)
|
2015-03-04 |
2020-11-09 |
Univ Texas |
Fremgangsmåder til behandling af cancer, som har hemizygot tab af tp53
|
US20180171294A1
(en)
*
|
2015-03-26 |
2018-06-21 |
The Trustees Of The University Of Pennsylvania |
In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
EP3302539A4
(de)
*
|
2015-05-22 |
2018-12-19 |
Brian J. Czerniecki |
Herstellung von injektionsfertigen mehrfachdosis-impfungen aus dendritischen zellen
|
US9993538B2
(en)
|
2015-05-29 |
2018-06-12 |
Galena Biopharma, Inc. |
Peptide vaccine therapy for treatment of FRα-expressing tumors
|
NZ738149A
(en)
|
2015-06-10 |
2024-02-23 |
Univ Texas |
Use of exosomes for the treatment of disease
|
RU2612015C2
(ru)
*
|
2015-06-29 |
2017-03-01 |
Общество с ограниченной ответственностью "Сибинтех" |
Пептид-иммуноген, используемый в терапевтической вакцине для лечения метастатического рака молочной железы у кошек и собак
|
AU2016298210B2
(en)
|
2015-07-28 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
|
WO2017040380A2
(en)
|
2015-08-28 |
2017-03-09 |
Research Development Foundation |
Engineered antibody fc variants
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
SG10202104058XA
(en)
|
2015-10-14 |
2021-05-28 |
Bio Path Holdings Inc |
P-ethoxy nucleic acids for liposomal formulation
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
RU2624862C2
(ru)
*
|
2015-10-20 |
2017-07-07 |
Общество с ограниченной ответственностью "Эпитек" |
Пептид-иммуноген, используемый в терапевтической вакцине для лечения метастатического рака молочной железы
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
EP3371221A2
(de)
|
2015-11-07 |
2018-09-12 |
MultiVir Inc. |
Verfahren und zusammensetzungen mit tumorsuppressorgentherapie und immuncheckpoint-blockade zur behandlung von krebs
|
JP6987068B2
(ja)
|
2015-11-09 |
2021-12-22 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia |
癌マーカーおよび治療標的としてのグリピカン2
|
CN108925136B
(zh)
|
2015-12-02 |
2022-02-01 |
斯特赛恩斯公司 |
特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体
|
CN109415437B
(zh)
|
2015-12-02 |
2022-02-01 |
斯特库伯株式会社 |
与btn1a1免疫特异性结合的抗体和分子及其治疗用途
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
CA3015839A1
(en)
|
2016-02-26 |
2017-08-31 |
The Board Of Regents Of The University Of Texas System |
Connexin (cx)43 hemichannel-binding antibodies and uses thereof
|
EP3423044A4
(de)
|
2016-03-02 |
2019-11-20 |
The Board of Regents of The University of Texas System |
Sting-aktivierender nanoimpfstoff zur immuntherapie
|
EP4273551A3
(de)
|
2016-03-25 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Multiplex-gesamtantikörper- und antikörper-konjugierter arzneimittelquantifizierungstest
|
US20190105403A1
(en)
|
2016-03-29 |
2019-04-11 |
Stcube & Co., Inc. |
Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
|
CN109195991B
(zh)
|
2016-03-29 |
2023-10-31 |
斯特库比股份有限公司 |
对糖基化pd-l1特异的双重功能抗体及其使用方法
|
WO2017176076A1
(en)
|
2016-04-06 |
2017-10-12 |
Ewha University - Industry Collaboration Foundation |
A peptide with ability to penetrate cell membrane
|
EP4029950A1
(de)
|
2016-04-29 |
2022-07-20 |
Board of Regents, The University of Texas System |
Gezielte messung der transkriptionellen aktivität im zusammenhang mit hormonrezeptoren
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017201449A1
(en)
|
2016-05-20 |
2017-11-23 |
Genentech, Inc. |
Protac antibody conjugates and methods of use
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
MA45169A
(fr)
|
2016-05-31 |
2019-04-10 |
Sellas Life Sciences Group Inc |
Thérapie vaccinale pour le traitement du cancer de l'endomètre et de l'ovaire
|
CN110234752A
(zh)
*
|
2016-06-03 |
2019-09-13 |
埃特彼塞斯公司 |
用于涉及her2/neu的肿瘤疫苗接种和免疫疗法的组合物和方法
|
CN109476648B
(zh)
|
2016-06-06 |
2022-09-13 |
豪夫迈·罗氏有限公司 |
司维司群抗体-药物缀合物和使用方法
|
CA3028771A1
(en)
|
2016-07-06 |
2018-01-11 |
Board Of Regents, The University Of Texas System |
Human-enzyme mediated depletion of cystine for treating patients with cystinuria
|
EP3487883B1
(de)
|
2016-07-20 |
2023-01-04 |
Stcube, Inc. |
Verfahren zur krebsbehandlung und therapie unter verwendung einer kombination von glykosyliertes pd-l1-bindenden antikörpern
|
CN109689111B
(zh)
|
2016-08-11 |
2024-04-05 |
基因泰克公司 |
吡咯并苯并二氮杂䓬前药及其抗体缀合物
|
US9963498B2
(en)
|
2016-08-18 |
2018-05-08 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
|
AU2017325971A1
(en)
|
2016-09-16 |
2019-04-11 |
Bio-Path Holdings, Inc. |
Combination therapy with liposomal antisense oligonucleotides
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
US11883430B2
(en)
|
2016-11-09 |
2024-01-30 |
Musc Foundation For Research Development |
CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
UA125198C2
(uk)
|
2017-02-08 |
2022-01-26 |
Ейдісі Терапьютікс Са |
Кон'югати піролобензодіазепін-антитіло
|
EP3586136B1
(de)
|
2017-02-24 |
2023-11-08 |
Board Of Regents, The University Of Texas System |
Test zum nachweis von pankreaskarzinom im frühstadium
|
SI3612537T1
(sl)
|
2017-04-18 |
2022-10-28 |
Medimmune Limited |
Konjugati pirolobenzodiazepina
|
CN110536703A
(zh)
|
2017-04-20 |
2019-12-03 |
Adc治疗有限公司 |
使用抗axl抗体-药物缀合物的组合疗法
|
US10865403B2
(en)
|
2017-05-12 |
2020-12-15 |
Board Of Regents, The University Of Texas System |
Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
|
CA3060988A1
(en)
|
2017-05-12 |
2018-11-15 |
Board Of Regents, The University Of Texas System |
Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
|
WO2018222685A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
US20200148768A1
(en)
|
2017-05-31 |
2020-05-14 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
CN110997724A
(zh)
|
2017-06-06 |
2020-04-10 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
BR112019026564A2
(pt)
|
2017-06-14 |
2020-06-30 |
Adc Therapeutics Sa |
regimes de dosagem para a administração de um adc anti-cd19
|
CN111065638B
(zh)
|
2017-08-18 |
2021-04-09 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂䓬缀合物
|
RU2020113749A
(ru)
|
2017-09-20 |
2021-10-20 |
пиЭйч ФАРМА Ко., ЛТД. |
Аналоги таиланстатина
|
EP3694545A4
(de)
|
2017-10-11 |
2021-12-01 |
Board Of Regents, The University Of Texas System |
Menschliche pd-l1-antikörper und verfahren zu ihrer verwendung
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
KR20200135986A
(ko)
|
2018-03-19 |
2020-12-04 |
멀티비르 인코포레이티드 |
종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
|
EP3768726A4
(de)
|
2018-03-23 |
2021-12-22 |
Board of Regents, The University of Texas System |
Antikörper mit doppelter spezifität für pd-l1 und pd-l2 und verwendungsverfahren dafür
|
BR112020019251A2
(pt)
|
2018-03-27 |
2021-01-12 |
Board Of Regents, The University Of Texas System |
Compostos com atividade anti-tumor contra células de câncer com mutações de her2 exon 19
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
CN108624589B
(zh)
*
|
2018-04-17 |
2021-12-17 |
广州永诺生物科技有限公司 |
环状RNA circ-ERBB2及其检测试剂与应用
|
CN108484732A
(zh)
*
|
2018-06-08 |
2018-09-04 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
CN108715603A
(zh)
*
|
2018-06-08 |
2018-10-30 |
天津亨佳生物科技发展有限公司 |
一种治疗肿瘤的抗原肽链组及其在药物中的应用
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
EP3870235A1
(de)
|
2018-10-24 |
2021-09-01 |
F. Hoffmann-La Roche AG |
Konjugierte chemische abbauauslöser und verwendungsverfahren
|
US20220033848A1
(en)
|
2018-11-19 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
CA3121027A1
(en)
|
2018-11-28 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
AU2019386830A1
(en)
|
2018-11-29 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
CN113227119A
(zh)
|
2018-12-10 |
2021-08-06 |
基因泰克公司 |
用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
KR20210125530A
(ko)
|
2019-02-08 |
2021-10-18 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
노화 및 연령-관련 기관 기능부전과 연관된 질환을 치료하기 위한 텔로머라제-함유 엑소좀
|
JP2022534555A
(ja)
|
2019-05-09 |
2022-08-02 |
フジフィルム セルラー ダイナミクス,インコーポレイテッド |
ヘパトサイトの作製方法
|
TW202110431A
(zh)
|
2019-05-17 |
2021-03-16 |
美商癌症預防製藥股份有限公司 |
治療家族性腺瘤性瘜肉症之方法
|
US20220257653A1
(en)
|
2019-07-19 |
2022-08-18 |
The Children's Hospital Of Philadelphia |
Chimeric antigen receptors containing glypican 2 binding domains
|
AU2020344675A1
(en)
|
2019-09-13 |
2022-03-31 |
Elektrofi, Inc. |
Compositions and methods for the delivery of therapeutic biologics for treatment of disease
|
US20220411511A1
(en)
|
2019-09-26 |
2022-12-29 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
US20220356248A1
(en)
|
2019-10-09 |
2022-11-10 |
Stcube & Co |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
WO2021087458A2
(en)
|
2019-11-02 |
2021-05-06 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
MX2022008412A
(es)
|
2020-01-07 |
2022-08-08 |
Univ Texas |
Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer.
|
WO2021167908A1
(en)
|
2020-02-17 |
2021-08-26 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
WO2021237068A2
(en)
|
2020-05-21 |
2021-11-25 |
Board Of Regents, The University Of Texas System |
T cell receptors with vgll1 specificity and uses thereof
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
EP4172370A1
(de)
|
2020-06-30 |
2023-05-03 |
Lunglife Ai, Inc. |
Verfahren zum nachweis von lungenkrebs
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
EP4243839A1
(de)
|
2020-11-13 |
2023-09-20 |
Catamaran Bio, Inc. |
Genetisch modifizierte natürliche killerzellen und verfahren zur verwendung davon
|
EP4251645A1
(de)
|
2020-11-25 |
2023-10-04 |
Catamaran Bio, Inc. |
Mit signalmodulatoren manipulierte zelluläre therapeutika und verfahren zur verwendung davon
|
EP4281116A1
(de)
|
2021-01-19 |
2023-11-29 |
William Marsh Rice University |
Knochenspezifische verabreichung von polypeptiden
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
WO2023014922A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
CN115925875A
(zh)
*
|
2021-08-20 |
2023-04-07 |
百奥赛图(北京)医药科技股份有限公司 |
Her2基因人源化非人动物及其构建方法和应用
|
WO2023060136A1
(en)
|
2021-10-05 |
2023-04-13 |
Cytovia Therapeutics, Llc |
Natural killer cells and methods of use thereof
|
CN113699221B
(zh)
*
|
2021-10-19 |
2023-10-10 |
广州吉赛医疗科技有限公司 |
HER2 mRNA及环状RNA多重荧光定量PCR检测引物探针及其应用
|
WO2023068382A2
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
CN114262689A
(zh)
*
|
2021-12-17 |
2022-04-01 |
上海纳米技术及应用国家工程研究中心有限公司 |
一种快速检测cd19/cd20-car-t细胞活性的方法
|
GB202201137D0
(en)
|
2022-01-28 |
2022-03-16 |
Thelper As |
Therapeutic and diagnostic agents and uses thereof
|
WO2023172514A1
(en)
|
2022-03-07 |
2023-09-14 |
Catamaran Bio, Inc. |
Engineered immune cell therapeutics targeted to her2 and methods of use thereof
|
WO2023192976A1
(en)
|
2022-04-01 |
2023-10-05 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
WO2023230531A1
(en)
|
2022-05-24 |
2023-11-30 |
Lunglife Ai, Inc. |
Methods for detecting circulating genetically abnormal cells
|
WO2023239940A1
(en)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|